Pretreatment of animals with cyclophosphamide (CY) can augment cell-mediate immunity to tumor-associated antigens. This immunopotentiating effect is probably caused by selective toxicity for T lymphocyte-mediated suppressor activity. We have shown that pretreatment of patients with advanced cancer with CY, either 1000 or 300 mg/M2, significantly augmented the development of delayed-type hypersensitivity (DTH) to the primary antigen, keyhole limpet hemocyanin (KLH). Furthermore, we observed that administration of CY 3 days prior to injection of an autologous tumor vaccine resulted in the acquisition of DTH to the autologous tumor cells in a group of patients with metastatic melanoma who did not become immunized without CY. To date, treatment with CY + vaccine has resulted in clinically important regression of metastases in 4/33 patients. Studies with peripheral blood lymphocytes (PBL) from these patients indicate that CY inhibits the generation of T suppressor cells, possibly by toxicity for a suppressor-inducer cell with the phenotype, CD4+,2H4+. We now propose to continue and extend these studies:
Specific aim 1) is to identify and characterize melanoma antigen-responsive suppressor T cells. We will exploit a recently developed method to test the effect of putative suppressors on in vitro responses to melanoma cells and an established technique utilizing suppressors elicited by melanoma cells but tested in a mitogen-activated indicator system.
Specific aim 2) is to determine whether heterogeneity of expression of melanoma-associated antigens is an important limitation to the effectiveness of active immunotherapy and whether it can circumvented by therapeutic modification.
Specific aim 3) is test the hypothesis that the response to tumor antigens can be augmented by immunizing with trinitrophenol-conjugated tumor cells in the absence of suppression, thereby inducing a population of amplified helper cells or possibly contrasuppressor cells. Finally, Specific aim 4) is an attempt to take advantage of the concept that tolerance to self-antigens, and perhaps tumor antigens as well, is HLA- restricted and can be reversed by presenting those antigens in the context of foreign HLA products, i.e., on allogeneic cells. We expect these studies to lead to more effective immunotherapy of human melanoma.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
2R01CA039248-04
Application #
3178074
Study Section
Experimental Therapeutics Subcommittee 2 (ET)
Project Start
1985-05-01
Project End
1993-04-30
Budget Start
1988-05-01
Budget End
1989-04-30
Support Year
4
Fiscal Year
1988
Total Cost
Indirect Cost
Name
Thomas Jefferson University
Department
Type
Schools of Medicine
DUNS #
061197161
City
Philadelphia
State
PA
Country
United States
Zip Code
19107
Coss, R A; Storck, C W; Wachsberger, P R et al. (2004) Acute extracellular acidification reduces intracellular pH, 42 degrees C-induction of heat shock proteins and clonal survival of human melanoma cells grown at pH 6.7. Int J Hyperthermia 20:93-106
Berd, David (2003) Contribution of dead cells to the immunogenicity of an autologous, hapten-modified melanoma vaccine. Vaccine 21:795-7
Coss, Ronald A; Storck, Christopher W; Daskalakis, Constantine et al. (2003) Intracellular acidification abrogates the heat shock response and compromises survival of human melanoma cells. Mol Cancer Ther 2:383-8
Wahl, Miriam L; Owen, Judith A; Burd, Randy et al. (2002) Regulation of intracellular pH in human melanoma: potential therapeutic implications. Mol Cancer Ther 1:617-28
Manne, Jayanthi; Mastrangelo, Michael J; Sato, Takami et al. (2002) TCR rearrangement in lymphocytes infiltrating melanoma metastases after administration of autologous dinitrophenyl-modified vaccine. J Immunol 169:3407-12
Han, J-S; Storck, C W; Wachsberger, P R et al. (2002) Acute extracellular acidification increases nuclear associated protein levels in human melanoma cells during 42 degrees C hyperthermia and enhances cell killing. Int J Hyperthermia 18:404-15
Berd, David (2002) M-Vax: an autologous, hapten-modified vaccine for human cancer. Expert Opin Biol Ther 2:335-42
Berd, David; Sato, Takami; Mastrangelo, Michael J (2002) Effect of the dose and composition of an autologous hapten-modified melanoma vaccine on the development of delayed-type hypersensitivity responses. Cancer Immunol Immunother 51:320-6
Berd, D; Sato, T; Cohn, H et al. (2001) Treatment of metastatic melanoma with autologous, hapten-modified melanoma vaccine: regression of pulmonary metastases. Int J Cancer 94:531-9
Berd, D; Maguire Jr, H C; Schuchter, L M et al. (1997) Autologous hapten-modified melanoma vaccine as postsurgical adjuvant treatment after resection of nodal metastases. J Clin Oncol 15:2359-70

Showing the most recent 10 out of 37 publications